TOKYO -- U.S. drugmaker Eli Lilly will launch a new obesity drug for patients with severe cases as soon as 2027, according to CEO David Ricks, who told Nikkei there is a rising need particularly in the U.S. for "something stronger" than currently available treatments.
Pharmaceuticals
Eli Lilly eyes 2027 approval for new obesity drug: CEO
US drugmaker sees Retatrutide as 'next chapter' in fast-growing sector
Eli Lilly CEO David Ricks said that demand for obesity drugs exists in Japan as well, citing the fact that one out of four adults there is overweight or obese. (Photo by Shintaro Ino)
Read Next
Latest on Pharmaceuticals
